Welcome to our dedicated page for Acumen Pharmaceuticals SEC filings (Ticker: ABOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Acumen files periodic reports and current reports with the U.S. Securities and Exchange Commission, including Forms 10‑K, 10‑Q and 8‑K, in connection with its development of sabirnetug (ACU193), a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs) for the treatment of early Alzheimer’s disease.
Through its 8‑K filings, Acumen reports material events such as quarterly financial results, business highlights, strategic collaboration agreements and changes in its Board of Directors. For example, recent 8‑Ks have covered the company’s financial condition, the posting of updated corporate presentations, and the appointment of a new chairman of the board. These filings complement press releases that discuss the progress of the Phase 2 ALTITUDE-AD trial, the Enhanced Brain Delivery (EBD™) collaboration with JCR Pharmaceuticals, and other corporate developments.
On this page, users can also track how Acumen describes its status as an emerging growth company, its listing of common stock on The Nasdaq Global Select Market under the symbol ABOS, and its use of collaborations and option agreements to support development of AβO-targeted therapies. While detailed insider trading information would appear in Form 4 filings and executive compensation in proxy materials, this hub focuses on the full range of EDGAR-reported documents.
Stock Titan enhances these filings with AI-powered summaries that explain key points, highlight important sections in lengthy reports such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q, and help readers quickly understand how new disclosures relate to Acumen’s Alzheimer’s disease programs and financial position.
Acumen Pharmaceuticals, Inc. is registering 10,833,331 shares of Common Stock for resale by selling stockholders that acquired the shares in a March 16, 2026 private placement. The prospectus states the company will not receive proceeds from these resales and that the selling stockholders will determine timing, price and method of disposition.
The prospectus notes 72,212,758 shares outstanding as of March 20, 2026 and discloses a March 31, 2026 last reported sale price of $2.36 per share. The registration is part of an S-3 shelf process and includes customary plan-of-distribution provisions and registration-rights obligations.
Acumen Pharmaceuticals, Inc. is registering the resale of up to 10,833,331 shares of its common stock.
This prospectus covers shares issued in a Private Placement completed on March 16, 2026 at $3.30 per share; the Company will not receive proceeds from resales. The Registration Rights Agreement commits the Company to keep the registration statement effective until the selling stockholders have resold the registrable securities or they can be resold under Rule 144.
Context: shares outstanding were 72,212,758 as of March 20, 2026, the Company’s common stock trades on Nasdaq Global Select (symbol ABOS), and the last reported sale price was $2.63 on March 25, 2026. The prospectus lists the selling stockholders and the permitted distribution methods; the Company will bear registration expenses.
Acumen Pharmaceuticals is a clinical-stage biopharma company focused on Alzheimer’s disease. Its lead and only clinical product candidate, sabirnetug (ACU193), is an Aβ oligomer–selective monoclonal antibody in the Phase 2 ALTITUDE-AD trial in early Alzheimer’s, with topline results expected in late 2026.
Phase 1 INTERCEPT-AD in early Alzheimer’s patients met primary and secondary objectives, showing dose-related amyloid plaque reduction, near-maximal target engagement at higher doses and an overall ARIA-E rate of 10.4%. The company is also advancing subcutaneous sabirnetug and a blood-brain barrier–penetrating EBD™ program, and has collaborations with Halozyme, JCR and Lonza. Acumen discloses substantial funding needs and an auditor “going concern” explanatory paragraph, and highlights heavy dependence on sabirnetug amid intense competition in Alzheimer’s therapies.
Acumen Pharmaceuticals reported a larger full-year 2025 net loss while funding late-stage Alzheimer’s programs. For the year ended December 31, 2025, the company recorded a net loss of $121.3 million, compared with $102.3 million in 2024, driven mainly by higher research and development spending.
R&D expenses rose to $104.9 million from $93.8 million, reflecting manufacturing, clinical and Enhanced Brain Delivery (EBD™) research costs, while G&A expenses declined slightly to $18.9 million. Cash, cash equivalents and marketable securities totaled $116.9 million as of December 31, 2025, which management expects to fund current clinical and operational activities into early 2027. A $35.75 million private placement in March 2026 further supports development.
The company’s lead antibody sabirnetug (ACU193) is being tested in the Phase 2 ALTITUDE-AD trial in early Alzheimer’s disease, with topline results expected in late 2026. Acumen is also advancing an EBD program that showed markedly higher brain exposure in non-human primates, with an IND filing for a lead clinical candidate targeted for mid-2027.
Acumen Pharmaceuticals, Inc. reported that investment entities associated with RA Capital Management, L.P. acquired 6,060,606 shares of common stock at $3.30 per share in a grant or award transaction on March 16, 2026. The shares are held indirectly, including by RA Capital Healthcare Fund, L.P., with 19,103,785 shares reported as held following the transaction. Additional indirect holdings include 1,300,034 shares held by RA Capital Nexus Fund II, L.P. and 588,850 shares held in a separately managed account. The Adviser entities and managing members disclaim beneficial ownership beyond their respective pecuniary interests.
RA Capital Management and affiliates filed Amendment No. 4 to their Schedule 13D on Acumen Pharmaceuticals. They report beneficial ownership of 21,101,669 shares of common stock, or 29.5% of the company, including 19,103,785 shares held by RA Capital Healthcare Fund.
The filing reflects a March 2026 private placement in which Acumen sold 10,833,331 shares at $3.30 per share. RA Capital Healthcare Fund purchased 6,060,606 of those shares for total consideration of $19,999,999.80. Acumen agreed to register these PIPE shares for resale under a registration rights agreement.
Acumen Pharmaceuticals is raising about $35.75 million through a private placement of 10,833,331 common shares at $3.30 per share with institutional investors. The deal is expected to close on March 16, 2026, subject to customary conditions. The company plans to use the proceeds primarily to advance its Enhanced Brain Delivery (EBD™) program, including preclinical work to select a lead clinical candidate, and for working capital and general corporate purposes. Acumen also granted investors registration rights to resell the new shares after the company files and clears a resale registration statement.
Acumen Pharmaceuticals’ Chief Legal Officer Derek M. Meisner exercised employee stock options for 2,090 shares of common stock at $1.85 per share and sold the same 2,090 shares at $3.26 per share.
These transactions were carried out automatically under a pre-arranged Rule 10b5-1 trading plan adopted on March 29, 2025. After the sale, Meisner directly holds 173,999 shares of Acumen common stock, indicating this was a relatively small, routine liquidity event.
Acumen Pharmaceuticals reported a proposed sale of 2,090 common shares via a broker-assisted cashless exercise on 03/06/2026. The filing lists prior open-market sales by Derek Meisner across January–February 2026, including large blocks of 36,911 shares on 01/08/2026 and 15,085 shares on 01/26/2026.